Trial Profile
A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary) ; Vilanterol/fluticasone furoate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 May 2017 Results of a post-hoc analysis from NCT01165138, NCT01686633 and NCT01134042 trials presented at the 113th International Conference of the American Thoracic Society
- 06 Dec 2013 Primary endpoint `superiority of vilanterol/fluticasone furoate 100/25 mcg vs fluticasone furoate in 0-24 hour weighted mean forced expiratory volume in one second (FEV1)' has been met, according to a Theravance media release.
- 06 Dec 2013 Data from this trial will support a potential filing for vilanterol/fluticasone furoate for the treatment of asthma in adults in the USA, according to a Theravance media release.